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Sir,
We have read with great interest the article published in your
journal titled ‘tumor response interpretation with new tumor
response criteria vs the World Health Organization criteria in
patients with bone-only metastatic breast cancer’ (Hamaoka et al,
2010). In this article the therapeutic response of breast cancer
patients with bone metastases was assessed by applying both the
new MDA response criteria (Hamaoka et al, 2004) that are based
on computed tomography (CT), magnetic resonance imaging
(MRI), plain radiography (XR) and skeletal scintigraphy (SS), and
the old World Health Organization (WHO) response criteria that
are based on XR and SS (WHO, 1979). The authors concluded
that the MDA classification system is superior to that of WHO in
differentiating between treatment responders and non-responders.
We are in total agreement with the authors that large prospective
studies should be carried out to establish the MDA criteria for
evaluating the therapeutic outcome of patients with bone
metastases. This need becomes more urgent if we consider that
the well-known Response Evaluation Criteria for Solid Tumors
(Therasse et al, 2000) do not include bone response evaluations.
Moreover, classifications such as the ones of the WHO and the
Union International Against Cancer (Hayward et al, 1977) were
described 30 years ago and do not include modern imaging
techniques such as the MRI, CT or positron emission tomography.
We would like to go a step further and comment on the MDA
classification response criteria as it is our opinion that they may
be improved by becoming more objective and accurate. Starting
with the application of CT for assessing bone metastases, it would
be very useful if the bone density in regions of metastases is
measured in Hounsfield units (HU) after delineation of affected
bone areas (region of interest technique, ROI). By comparing
bone density measurements before, during and after treatment
(Vassiliou et al, 2007a,b; Chow et al, 2004), researchers would
be able to monitor changes of bone density objectively and follow
the therapeutic response more accurately.
For osteolytic lesions an increase in bone density up to at least the
level of bone density of neighbouring healthy bones would mean a
complete response, whereas an increase in absolute numbers would
indicate a partial response. In the case that bone density remains
unaltered, stable disease should be considered. Finally, in the event
that bone density decreases, disease progression should be
indicated. In the case of osteoblastic lesions a decrease in bone
density up to at least the level of bone density of neighbouring
healthy bones would mean a complete response, whereas a
reduction of bone density would mean a partial response. As in
the case of lytic bone lesions, if bone density remains unchanged,
stable disease should be considered, whereas when there is an
increase in bone density, disease progression should be indicated.
The MDA response criteria are not so objective as they are rather
descriptive and do not use specific quantitative measurements. For
example, a complete response is considered to be a ‘normalisation
of osteoblastic lesion’ or a ‘complete fill-in or sclerosis of a lytic
lesion on CT’. A partial response is considered to be a ‘partial fill-in
or sclerosis of a lytic lesion on CT’ or a ‘regression of a measurable
blastic lesion on CT’, whereas in cases that no changes are observed
on CT, stable disease is indicated.
Comments on the use of MRI for assessing the therapeutic
response of bone metastases in association with the MDA criteria
also aim to improve objectivity. This could be improved by
measuring and monitoring absolute or percentage changes of
signal intensities in delineated bone metastases (ROI) after
applying a specific MRI sequence with or without contrast
enhancement. As in the case of CT, this could be carried out
before treatment as well as during and after completion of therapy
for comparative purposes. A number of studies that used this
methodology have been published (Vassiliou et al, 2007a; Brown
et al, 1998; Ciray et al, 2001; Montemuro et al, 2004) and for the
sake of discussion we present only one. In the study by Vassiliou
et al, patients with bone metastases were evaluated with MRI
before and 3 months after the onset of radiotherapy combined with
monthly bisphosphonate infusions. At 3 months signal intensities
of T1TSE images (with and without gadolinium (Gd) enhance-
ment) were significantly lower than corresponding baseline values
(Po0.001), indicating a response to therapy. More specifically,
Gd enhancement was associated with a 57% increase at baseline as
compared to only 15% at 3 months.
Both the measurement of bone density (CT) and signal intensity
(MRI) of bone metastases after ROI delineation are effaceable and
have been successfully used to evaluate the therapeutic response of
patients with metastatic bone lesions. Their probable incorporation
in the MDA criteria would improve accuracy and objectivity. Published online 27 July 2010
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